Gossamer Bio, Inc.
GOSSGossamer Bio is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutic options for pulmonary hypertension.
Table of contents
Earnings
Next report
Aug 4, 2026 (In 3 weeks)Competitors
By market cap
By revenue growth
Profile
Gossamer Bio is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutic options for pulmonary hypertension. The company's primary focus is on seralutinib, a drug candidate designed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Their value proposition centers on leveraging a management team with deep expertise in rare disease drug development to address significant unmet needs in the PH patient population.
A clinical-stage developer focused on high-risk subgroups within the pulmonary arterial hypertension market, currently navigating Phase 3 data analysis and regulatory alignment.
Questions, answered.
- What is Gossamer Bio, Inc.'s market cap?
- Gossamer Bio, Inc. (GOSS) has a market capitalization of $85.5M and trades on NASDAQ.
- Who are Gossamer Bio, Inc.'s competitors?
- Gossamer Bio, Inc.'s key competitors include United Therapeutics, Merck & Co., Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Who does Gossamer Bio, Inc. partner with?
- Gossamer Bio, Inc.'s notable partners include U.S. Food and Drug Administration.
- Where is Gossamer Bio, Inc. headquartered?
- Gossamer Bio, Inc. is headquartered in United States of America and employs approximately 135 people. It has been publicly traded since 2019.